Investor Center
Soligenix, Inc.’s common stock is listed on Nasdaq under the symbol SNGX. Stockholders and interested parties are urged to contact our main office in Princeton, New Jersey at 609-538-8200 or send an e-mail to ir@nullsoligenix.com for further information.
Dr. Christopher Schaber, President & CEO of Soligenix Inc. talks about the company’s activities. Video provided courtesy of Thomson Reuters Insider Network
Company Presentations
- April 23, 2019: View the Corporate Presentation (pdf)
- November 26, 2018: Watch the “Review of IDR Mechanism of Action and Potential Therapeutic Applications” presentation on YouTube
- November 14, 2018: Watch the “Thermostabilized Vaccine Development under the Animal Rule: Ricin Toxin Vaccine” presentation on YouTube
- November 13, 2017: Watch the “Innate defense regulators: Broad-spectrum, host-directed therapy for antibiotic resistant disease” presentation on YouTube
- September 14, 2017: Watch the “Innate Defense Regulators As An Agnostic Therapy To Treat Bacterial Infections And Fight Resistance” presentation on YouTube
- July 13, 2017: Watch the “Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease” presentation on YouTube
- March 20, 2017: Watch the “Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease” presentation on YouTube
- December 16, 2016: Watch the “Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis” Webcast on YouTube
Financial and Corporate Governance Information
- Soligenix Stock Quote (Website link)
- Soligenix Filings with the SEC (Website link)
- Code of Ethics
- Audit Committee Charter (PDF)
- Compensation Committee Charter (PDF)
- Nominating Committee Charter (PDF)
- Director Compensation and Stock Ownership Policy (PDF)
Literature Request
If you would like to receive our Investor Relations Packet, including reprints of scientific publications relating to our products, click here. Thank you for your interest.